Marvel Biosciences Corp. announced the creation of its scientific advisory board to help guide the development of its lead asset, MB-204, a fluorinated derivative of the US-FDA approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world, whose consumption has been associated with a reduced risk for developing Parkinson's disease, Alzheimer's disease and improving concentration. The scientific advisory board members include: Dr. David Blum adds crucial depth to the scientific board for his highly relevant research in the A2A receptor antagonists in cognition, brain lesions, and tau pathology for applications in Alzheimer's Disease (AD). Dr. Jared Young, Ph.D., is a Professor in the Department of Psychiatry at the University of California San Diego and brings significant expertise to the scientific board as a leader in ranslational models to validate drugs developed for neuropsychiatric disorders. Professor Bruce N. Cronstein, MD, is a Professor at the NYU Grossman School of Medicine (for the Departments of Medicine, Pharmacology, and Pathology). Professor Frank Schweizer is a Professor of Chemistry in the Department of Chemistry and Medical Microbiology & Infectious Diseases at the University of Manitoba.